Monday, September 21, 2020
Health

Lupin launches COVID-19 drug Favipiravir in India at ₹49 per tablet

Lupin launches COVID-19 drug Favipiravir in India at ₹49 per tablet
4views


Favipiravir has received authorisation from DCGI for emergency use, Lupin said in a regulatory filing.

Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name ‘Covihalt’ for the treatment patients with mild to moderate COVID-19 symptoms at ₹49 per tablet in India.

Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing.

Its Covihalt dosage strength has been developed keeping in mind convenience of administration, it stated, adding that the drug is available as 200 mg tablets in the form of a strip of 10 tablets, and priced at ₹49 per tablet.

Lupin President – India Region Formulations (IRF) Rajeev Sibal said the company believes that it can leverage its expertise in managing widespread community diseases like tuberculosis to proactively reach patients across India and ensure access to Covihalt through its strong distribution network and field force.

On August 4, Sun Pharmaceutical Industries had launched Favipiravir under the brand name “FluGuard” for the treatment of mild to moderate cases of COVID-19, at ₹35 per tablet in India.

Shares of Lupin were trading 0.32% higher at ₹943.70 apiece on BSE.

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Show Less Plan

Subscription Benefits Include

Today’s Paper

Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.

Faster pages

Move smoothly between articles as our pages load instantly.

Unlimited Access

Enjoy reading as many articles as you wish without any limitations.

Dashboard

A one-stop-shop for seeing the latest updates, and managing your preferences.

Personalised recommendations

A select list of articles that match your interests and tastes.

Briefing

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.



Source link

Leave a Response